Frazier Life Sciences Management L.P. boosted its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,943,774 shares of the company’s stock after purchasing an additional 241,818 shares during the quarter. NewAmsterdam Pharma makes up 16.0% of Frazier Life Sciences Management L.P.’s holdings, making the stock its largest position. Frazier Life Sciences Management L.P. owned about 14.94% of NewAmsterdam Pharma worth $594,388,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Capital World Investors boosted its position in NewAmsterdam Pharma by 17.1% during the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after purchasing an additional 1,434,986 shares in the last quarter. Handelsbanken Fonder AB boosted its position in NewAmsterdam Pharma by 18.8% during the third quarter. Handelsbanken Fonder AB now owns 405,800 shares of the company’s stock worth $11,541,000 after purchasing an additional 64,200 shares in the last quarter. American Century Companies Inc. boosted its position in NewAmsterdam Pharma by 17.1% during the third quarter. American Century Companies Inc. now owns 624,285 shares of the company’s stock worth $17,755,000 after purchasing an additional 91,369 shares in the last quarter. Aberdeen Group plc boosted its position in NewAmsterdam Pharma by 10.2% during the fourth quarter. Aberdeen Group plc now owns 729,484 shares of the company’s stock worth $25,590,000 after purchasing an additional 67,538 shares in the last quarter. Finally, UBS Group AG boosted its position in NewAmsterdam Pharma by 17.0% during the fourth quarter. UBS Group AG now owns 899,442 shares of the company’s stock worth $31,552,000 after purchasing an additional 130,922 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.
Insider Buying and Selling at NewAmsterdam Pharma
In other news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 12.74% of the company’s stock.
NewAmsterdam Pharma Stock Up 0.5%
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The business had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. As a group, sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the company. HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Guggenheim raised their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Truist Financial assumed coverage on NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price on the stock. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Needham & Company LLC raised their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $48.60.
View Our Latest Research Report on NewAmsterdam Pharma
NewAmsterdam Pharma Profile
NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.
The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
